Moderna & Pfizer commence late-stage COVID-19 vaccine trials in U.S.
Category: #health  By Saipriya Iyer  Date: 2020-07-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Moderna & Pfizer commence late-stage COVID-19 vaccine trials in U.S.

Moderna, a biotechnology company, and NIH (National Institute of Health) have reportedly collaborated to start the Phase 3 clinical trial of a potential COVID-19 vaccine.

The trial will examine the safety and efficacy of the vaccine in the U.S. It will enroll 30,000 subjects at over 89 sites across the country. Half the participants will receive 2 shots of their vaccine 28 days apart, while the other half will receive 2 shots of the saltwater placebo. Researchers will then monitor the occurrence of any adverse events as well as the effectiveness of the vaccine to determine whether it can prevent the COVID-19 disease.

Dr. Anthony S. Fauci, director of NIH, has estimated that the results or data from the Moderna trial are expected to be available by November 2020. He has further stated that 150-160 COVID-19 infections will be enough for determining the effectiveness of the vaccine.

Apart from Moderna, Pfizer also has recently announced the commencement of a late-stage COVID-19 vaccine trial, in collaboration with BioNTech. For this study, the company will enroll 30,000 participants from 39 U.S. states as well as from Germany, Argentina, and Brazil.

The U.S. government previously announced that it had signed a $1.95 billion agreement with Pfizer to buy 100 million doses of its vaccine by 2020 end if the trial proves the safety and efficacy of the vaccine. Both Pfizer/BioNTech and Moderna vaccines adopt a synthetic version of the genetic material from the virus, also known as mRNA (messenger RNA).

Earlier trials of the vaccine by Moderna revealed the stimulation of a strong immune response by the subjects, with transient and minor side effects including fatigue, fever, achiness, and sore arms. The biotech company has cited that it would deliver nearly 500 million vaccine doses per year and increase it up to a billion per year from 2021. It also obtained a $1 billion funding from the federal government for vaccine development.

Source credit:

https://www.nytimes.com/2020/07/27/health/moderna-vaccine-covid.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Target and Kohl’s to sell beauty products as department stores reel
Target and Kohl’s to sell beauty products as department stores reel
By Saipriya Iyer

Some retailers are speculating that eye shadow palettes, facial scrubs, and lip glosses will likely be the upcoming popular thing that would bring significant customer attention, especially the younger generation, to t...

U.S. FDA approves adjunctive therapy & intravenous use of VIMPAT®
U.S. FDA approves adjunctive therapy & intravenous use of VIMPAT®
By Saipriya Iyer

UCB, a biopharmaceutical company, has recently gained the approval of the U.S. FDA (Food & Drug Administration) for its prescription medicine, VIMPAT®.

VIMPAT

ECA alleges Amazon misused non-public data of retailers to its benefit
ECA alleges Amazon misused non-public data of retailers to its benefit
By Saipriya Iyer

The ECA (European Competition Authorities), in preliminary findings, has reportedly alleged that American e-commerce giant Amazon “systematically relied on non-public business information of independent sellers&r...